Where can I buy Atos shares?
Shares of ATOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What does Atos do?
It specialises in hi-tech transactional services, unified communications, cloud, big data and cybersecurity services. Atos operates worldwide under the brands Atos, Atos|Syntel, Atos Consulting, Atos Healthcare, Atos Worldgrid, Groupe Bull, Canopy and Unify .
Who is the CEO of Atos?
The CEO is Philippe Llorens. In 2011 Atos introduced a Zero Email initiative, banning email as a form of internal communications, except for use with customers and prospects. As part of the initiative, Atos acquired the French software company blueKiwi in early 2012, rolling out their ZEN social networking software across its organisation.
What is the history of the Atos acquisitions?
A diagram of the history of Atos acquisitions. The company was formed in 1997 through a merger of two French IT companies; and combined with the Dutch-based company Origin B.V. in 2000 to become Atos Origin.
See more
Is Atos a good stock to buy?
Is ATOSSA THERAPEUTICS Stock a good buy in 2022, according to Wall Street analysts? The consensus among 1 Wall Street analyst covering (NASDAQ: ATOS) stock is to Strong Buy ATOS stock.
What is the target price for Atos?
$7.50Stock Price Target ATOSHigh$7.50Median$7.50Low$7.50Average$7.50Current Price$1.02
Why is Atos stock dropping?
Shares of Atossa Therapeutics (NASDAQ: ATOS) were tumbling 22.8% as of 11:36 a.m. EDT on Wednesday. The decline came after the company announced final results from its phase 2 clinical study evaluating oral endoxifen in treating breast cancer with administration between diagnosis and surgery.
Will Atos go up?
Based on our forecasts, a long-term increase is expected, the "ATOS" stock price prognosis for 2027-05-26 is 1.755 USD. With a 5-year investment, the revenue is expected to be around +84.36%. Your current $100 investment may be up to $184.36 in 2027. Get It Now!
Is Galt a good stock?
The financial health and growth prospects of GALT, demonstrate its potential to underperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Does Atos recover?
'The new Atos' is on the way to recovery in 2022, CEO says.
Will Atos be added to Russell 2000?
(Nasdaq:ATOS), a clinical stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, today announced it is set to be added to the Russell 2000 and Russell 3000 Indexes This milestone will take place ...
Is Atos being shorted?
Short Shares Availability This table shows the number of shares of US:ATOS available to be shorted at a leading prime brokerage.
How many shares does Senseonics have?
Share StatisticsAvg Vol (3 month) 35.59MShares Outstanding 5463.26MImplied Shares Outstanding 6N/AFloat 8407.5M% Held by Insiders 17.74%7 more rows
When is Atossa Therapeutics' next earnings date?
Atossa Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for A...
How were Atossa Therapeutics' earnings last quarter?
Atossa Therapeutics, Inc. (NASDAQ:ATOS) announced its quarterly earnings data on Monday, May, 9th. The company reported ($0.04) earnings per share...
When did Atossa Therapeutics' stock split? How did Atossa Therapeutics' stock split work?
Atossa Therapeutics shares reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of...
Who are Atossa Therapeutics' key executives?
Atossa Therapeutics' management team includes the following people: Dr. Steven C. Quay FCAP , M.D., Ph.D., Chairman, CEO & Pres (Age 71, Pay $1....
What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?
8 employees have rated Atossa Therapeutics CEO Steven C. Quay on Glassdoor.com . Steven C. Quay has an approval rating of 53% among Atossa Therape...
Who are some of Atossa Therapeutics' key competitors?
Some companies that are related to Atossa Therapeutics include Rallybio (RLYB) , Nkarta (NKTX) , Nuvalent (NUVL) , Adicet Bio (ACET) , RAPT Th...
What other stocks do shareholders of Atossa Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuti...
What is Atossa Therapeutics' stock symbol?
Atossa Therapeutics trades on the NASDAQ under the ticker symbol "ATOS."
Who are Atossa Therapeutics' major shareholders?
Atossa Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.45%...
About Atossa Therapeutics
Atossa Therapeutics (NASDAQ:ATOS) Frequently Asked Questions
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.
Shares
Atossa Therapeutics' stock was trading at $0.88 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ATOS stock has increased by 43.2% and is now trading at $1.26. View which stocks have been most impacted by COVID-19.
Follow the Atos SE share performance on a customized investment horizon
Atos SE shares are traded on the Paris Euronext Market under code ISIN FR0000051732. The shares have been listed in Paris since 1995.
Signals & Forecast
Atos SE shares are traded on the Paris Euronext Market under code ISIN FR0000051732. The shares have been listed in Paris since 1995.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Wednesday, February 23, 2022, and so far it has risen 7.76%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is Atossa Genetics Inc. stock A Buy?
Atossa Genetics Inc. finds support from accumulated volume at $1.24 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are positive buying more shares than they are selling in Atossa Genetics Inc
Atossa Genetics Inc. holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Atossa Genetics Inc
In the last 100 trades there were 15.09 million shares bought and 3.27 million shares sold. The last trade was done 652 days ago by Weaver Gregory L who bough 70 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Atossa Genetics Inc., a clinical-stage pharmaceutical company, focuses on developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions in the United States.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
A Promising Breast Cancer Treatment
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
The Bottom Line on ATOS Stock
Atossa is developing Endoxifen, which the company hopes will become a treatment for some breast cancer patients. Endoxifen is a metabolite of Tamoxifen, which has gotten the nod from the FDA and has been used as a breast cancer treatment for a relatively small number of patients for over four decades.
History
Atossa, which had no revenue last year and is not expected to generate any sales any time soon, has a market capitalization of over $470 million.
Controversy
The company was formed in 1997 through a merger of two French IT companies; and combined with the Dutch-based company Origin B.V. in 2000 to become Atos Origin. It subsequently acquired KPMG Consulting in 2002 and SchlumbergerSema in 2004.
Sponsorship
In the United Kingdom, from 1998 to 2015, Atos Healthcare was at the centre of a controversy over the management of contracts by their healthcare division of the Work Capability Assessment (WCA) for the Department for Work and Pensions (DWP).
